Atrium Therapeutics RNA
-23.1%vs Day 1Spinoff of Avidity Bio (RNA) · Pre-Acquisition Spin · Spun Feb 26, 2026
Current Stats
Post-Spinoff Performance
| Spinoff date | February 26, 2026 · Nasdaq |
| Days since spinoff | 165 days |
| Day 1 price (open) | $14.75 |
| Post-spin low | $11.18 on Jul 29, 2026 · 151 days post-spin |
| Current price (Jul 31, 2026) | $11.35 |
| Return vs Day 1 | -23.1% |
| Return vs post-spin low | +1.5% |
| Parent since spinoff | — |
Price History
yfinance (auto-adjusted close + volume). As of Aug 10, 2026.
Post Spin Analysis
Compiled from tracked data as of the July 31, 2026 close.
The move
Atrium Therapeutics separated from Avidity Bio (RNA) on February 26, 2026 as a pre-acquisition spin, listing on Nasdaq. It closed its first regular-way session at $14.75 and set a post-spin low of $11.18 on Jul 29, 2026, 151 days after the spin. It last traded at $11.35 (Jul 31, 2026), -23.1% against the Day-1 close and +1.5% off the low.
The low came 151 days out — well beyond the usual forced-selling window, which points at something structural rather than mechanical selling pressure.
What we graded it
Covered in a single report before separation. Current rating: SPECULATIVE.
⚠ Auto-generated profile — not editorially reviewed.
This summary is compiled automatically from our tracked report data. A reviewed in-depth profile is planned. For further detail ▸ read the May 31, 2026 report.